* Sigma and Chemist Warehouse in $5.8 bln merger * Sigma to acquire Chemist Warehouse in a cash and scrip transaction * Sigma also undertaking a A$400 mln capital raising (Adds deal and capital raising details from paragraph 3) By Scott Murdoch and Echha Jain Dec 11 (Reuters) - Australia's Sigma Healthcare on Monday said it would merge with privately owned pharmacy giant Chemist Warehouse Group to create a A$8.8 billion ($5.79 billion) entity. Chemist Warehouse will own 85.8% of the merged company that will supply 1,000 Sigma-aligned pharmacies and own 600 Chemist Warehouse outlets, according to a statement. Chemist Warehouse is a pharmacy and retail chain in Australia known for cheap prices, large stores and major advertising campaigns. It has long been touted as a potential initial public offering (IPO) candidate but the Sigma deal gives it a backdoor way to being listed on the Australian Securities Exchange (ASX) at a time when global capital markets remain in the doldrums. The proposed merger has Sigma acquiring Chemist Warehouse in exchange for a stake in the company and A$700 million in cash. Sigma is raising A$400 million at A70c per share, which is an 8.2% discount to the stock's last closing price on Wednesday before it went into a trading halt. The capital raising is underwritten by Goldman Sachs and partly underwritten by Sigma major shareholder HMC. About 572.6 million shares will be issued in the capital raising, which equates to 54.1% of Sigma's existing shares on issue. Sigma said it had also signed a A$1 billion loan with ANZ Group and National Australia Bank to help fund the deal and cover Chemist Warehouse's existing debt. The deal requires Australian Competition and Consumer Commission (ACCC) approval and 75% support from Sigma's shareholders. The antitrust regulator has been taking an increasingly tough stance toward approval deals in sectors where competition is already concentrated. The proposed merger will create savings initially estimated at about A$60 million per annum, expected to be realized after four years. The aggregate annual historical earnings before interest and tax of the merged company would be more than A$495 million, before synergies, Sigma said. Chemist Warehouse founders Mario Verrocchi and Jack Gance would hold executive positions on the board of the merged company, Sigma said. The Sigma board unanimously recommends that shareholders vote in favour of the merger, the company said. Major shareholders HMC Capital and HMC Capital Partners Fund I would support the proposed merger in the absence of a superior proposal, Sigma said. ($1 = 1.5209 Australian dollars) (Reporting by Echha Jain in Bengaluru; Editing by Maju Samuel, Lisa Shumaker, Mark Porter and Marguerita Choy)
UPDATE 3-Australia's Sigma Healthcare signs $5.8 bln merger deal with Chemist Warehouse
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...